Verve Therapeutics Inc (NASDAQ: VERV)’s stock price has increased by 7.75 compared to its previous closing price of 4.45. However, the company has seen a 9.98% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-02 that BOSTON, June 02, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Verve Therapeutics Inc (NASDAQ: VERV) Right Now?
Moreover, the 36-month beta value for VERV is 1.67. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VERV is 65.76M and currently, short sellers hold a 27.99% of that float. On June 03, 2025, VERV’s average trading volume was 3.20M shares.
VERV’s Market Performance
VERV’s stock has seen a 9.98% increase for the week, with a -12.82% drop in the past month and a -22.29% fall in the past quarter. The volatility ratio for the week is 5.88%, and the volatility levels for the past 30 days are at 6.22% for Verve Therapeutics Inc The simple moving average for the past 20 days is 8.31% for VERV’s stock, with a -15.24% simple moving average for the past 200 days.
Analysts’ Opinion of VERV
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VERV reach a price target of $15. The rating they have provided for VERV stocks is “Buy” according to the report published on April 08th, 2024.
Canaccord Genuity gave a rating of “Buy” to VERV, setting the target price at $29 in the report published on April 13th of the previous year.
VERV Trading at 4.01% from the 50-Day Moving Average
After a stumble in the market that brought VERV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.47% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERV starting from Kathiresan Sekar, who sale 9,822 shares at the price of $4.15 back on Apr 02 ’25. After this action, Kathiresan Sekar now owns 346,686 shares of Verve Therapeutics Inc, valued at $40,761 using the latest closing price.
Nickerson Joan, the Chief Administrative Officer of Verve Therapeutics Inc, sale 2,777 shares at $4.15 during a trade that took place back on Apr 02 ’25, which means that Nickerson Joan is holding 17,420 shares at $11,525 based on the most recent closing price.
Stock Fundamentals for VERV
Current profitability levels for the company are sitting at:
- -3.5 for the present operating margin
- 0.36 for the gross margin
The net margin for Verve Therapeutics Inc stands at -3.04. The total capital return value is set at -0.37. Equity return is now at value -34.26, with -26.89 for asset returns.
Based on Verve Therapeutics Inc (VERV), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08.
Currently, EBITDA for the company is -221.91 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 6.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.84.
Conclusion
To wrap up, the performance of Verve Therapeutics Inc (VERV) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
